~ Buy the TRELSTAR (triptorelin pamoate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR TRELSTAR

All Clinical Trials for Trelstar

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01467882 ↗	Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty	Completed	Debiopharm International SA	Phase 3	2012-04-01	The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
NCT02090114 ↗	RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)	Recruiting	National Cancer Institute (NCI)	Phase 2	2014-06-01	Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
NCT02090114 ↗	RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)	Recruiting	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2014-06-01	Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).

Clinical Trial Conditions for Trelstar

Condition Name

Condition Name for Trelstar
Intervention	Trials
Prostate Cancer	6
Prostate Adenocarcinoma	2
Castration Resistant Metastatic Prostate Cancer	2

Condition MeSH

Condition MeSH for Trelstar
Intervention	Trials
Prostatic Neoplasms	10
Adenocarcinoma	2
Puberty, Precocious	1

Clinical Trial Locations for Trelstar

Trials by Country

Trials by Country for Trelstar
Location	Trials
United States	45
Canada	5
Mexico	1
Chile	1

Trials by US State

Trials by US State for Trelstar
Location	Trials
California	6
Maryland	5
New Jersey	3
District of Columbia	3
Washington	2

Clinical Trial Progress for Trelstar

Clinical Trial Phase

Clinical Trial Phase for Trelstar
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Trelstar
Clinical Trial Phase	Trials
Recruiting	4
Active, not recruiting	2
Terminated	2

Clinical Trial Sponsors for Trelstar

Sponsor Name

Sponsor Name for Trelstar
Sponsor	Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	5
National Cancer Institute (NCI)	3
United States Department of Defense	3

Sponsor Type

Sponsor Type for Trelstar
Sponsor	Trials
Other	13
Industry	5
U.S. Fed	3